<p>Voya Investment Management LLC 在最近向證券交易委員會提交的 13F 表格中表示，在第四季度將其在 Madrigal Pharmaceuticals, Inc.（NASDAQ:MDGL - 免費報告）中的股份削減了 77.2%。該基金在此期間售出了 33,672 股後，持有 9,942 股該生物製藥公司的股票。Voya Investment Management LLC 在 Madrigal Pharmaceuticals 的持股在最近一個季度末價值 306.8 萬美元。</p>
<ul>
<li>諾和諾德：GLP-1 銷售的新動力即將到來</li>
</ul>
<p>其他機構投資者最近也增持或減持了該公司的股份。FMR LLC 在第四季度將其在 Madrigal Pharmaceuticals 的股份增加了 10.8%。FMR LLC 目前持有 867,850 股該生物製藥公司的股票，價值 267,792,000 美元，此前在上個季度增持了 84,305 股。Geode Capital Management LLC 在第四季度將其在 Madrigal Pharmaceuticals 的股份增加了 1.2%。Geode Capital Management LLC 目前持有 410,578 股該生物製藥公司的股票，價值 126,719,000 美元，此前增持了 4,923 股。William Blair Investment Management LLC 在第四季度購買了 Madrigal Pharmaceuticals 的新頭寸，價值 114,717,000 美元。Rock Springs Capital Management LP 在第四季度將其在 Madrigal Pharmaceuticals 的持倉提高了 0.8%。Rock Springs Capital Management LP 目前持有 265,212 股該生物製藥公司的股票，價值 81,836,000 美元，此前增持了 2,150 股。最後，Pictet Asset Management Holding SA 在第四季度將其在 Madrigal Pharmaceuticals 的持股提高了 38.4%。Pictet Asset Management Holding SA 目前持有 208,484 股該生物製藥公司的股票，價值 64,332,000 美元，此前增持了 57,886 股。對沖基金和其他機構投資者持有該公司 98.50% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>MDGL 已經成為多份研究報告的主題。JMP Securities 在 4 月 24 日的研究報告中重申了對 Madrigal Pharmaceuticals 的 “市場表現優於大盤” 評級，並給出了 443.00 美元的目標價。B. Riley 在週五重新發布了 “買入” 評級，並將 Madrigal Pharmaceuticals 的目標價從 422.00 美元上調至 460.00 美元。Canaccord Genuity Group 在週五將 Madrigal Pharmaceuticals 的目標價從 394.00 美元上調至 420.00 美元，並給予該股票 “買入” 評級。HC Wainwright 在 2 月 27 日的研究報告中將 Madrigal Pharmaceuticals 的目標價從 400.00 美元上調至 405.00 美元，並給予該股票 “買入” 評級。最後，花旗集團在 2 月 27 日的研究報告中將 Madrigal Pharmaceuticals 的目標價從 378.00 美元上調至 469.00 美元，並給予該股票 “買入” 評級。一位分析師對該股票給予了賣出評級，一位給予了持有評級，九位給予了買入評級。根據 MarketBeat 的數據，Madrigal Pharmaceuticals 目前的平均評級為 “適度買入”，平均目標價為 416.33 美元。</p>
<ul>
<li>7 只將推動減肥藥市場的股票</li>
</ul>
<p><strong>閲讀我們關於 Madrigal Pharmaceuticals 的最新股票報告</strong></p>
<h2>內部人士買賣</h2>
<p>在其他消息中，副總裁 Robert E. Waltermire 在 3 月 5 日的交易中出售了 14,113 股公司的股票。這些股票以平均價格 341.32 美元出售，總價值為 4,817,049.16 美元。出售後，副總裁現在直接持有 3,728 股公司的股票，價值 1,272,440.96 美元。這代表了其持倉的 79.10% 的減少。該交易在向證券交易委員會的法律文件中披露，該文件可通過 SEC 網站訪問。此外，董事 James M. Daly 在 2 月 27 日的交易中出售了 15,470 股公司的股票。這些股票以平均價格 347.45 美元出售，總交易額為 5,375,051.50 美元。交易後，董事現在直接持有 1,912 股公司的股票，價值約 664,324.40 美元。這筆交易代表了其持倉的 89.00% 的減少。該出售的披露信息可以在這裏找到。內部人士在上個季度出售了 30,810 股公司股票，價值 10,610,594 美元。22.80% 的股票目前由公司內部人士持有。</p>
<h2>Madrigal Pharmaceuticals 股票下跌 3.7%</h2>
<ul>
<li>分析師預計這兩隻中型生物科技股票將獲得超過 50% 的收益</li>
</ul>
<p>MDGL 股票在週五開盤價為 315.48 美元。該公司的速動比率為 5.93，流動比率為 5.98，債務與股本比率為 0.15。Madrigal Pharmaceuticals, Inc.的 52 周低點為 200.08 美元，52 周高點為 377.46 美元。該股票的市值為 69.7 億美元，市盈率為-12.58，貝塔值為-0.69。該公司有 50 日移動平均線為 325.65 美元，200 日移動平均線為 313.96 美元。</p>
<p>Madrigal Pharmaceuticals（NASDAQ:MDGL - 獲取免費報告）最近在 5 月 1 日公佈了其季度財報。該生物製藥公司報告本季度每股收益為（3.32 美元），超過分析師一致預期的（3.62 美元）0.30 美元。該公司本季度的收入為 1.3725 億美元，而分析師的預期為 1.1279 億美元。在去年同期，該公司每股收益為（7.38 美元）。賣方分析師預測 Madrigal Pharmaceuticals, Inc.在本年度將發佈-23.47 美元的每股收益。</p>
<h2>Madrigal Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Madrigal Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於開發用於治療美國非酒精性脂肪肝炎（NASH）的治療藥物。其主要產品候選藥物為 resmetirom，一種針對肝臟的甲狀腺激素受體β激動劑，目前正在進行 NASH 的第三階段臨牀試驗。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票，而非 Madrigal Pharmaceuticals</li>
<li>大型股的定義及投資方式</li>
<li>Meta 在第一季度財報中表現出色 - 注意第二季度的關税影響</li>
<li>加拿大便士股票：它們能讓你致富嗎？</li>
<li>亞馬遜財報：兩個值得喜愛的理由，一個需要謹慎的理由</li>
<li>CD 計算器：定期存款計算器</li>
<li>Palantir 財報：一個看漲信號和一個關注領域</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Madrigal Pharmaceuticals 嗎？</h2>
<p>在考慮 Madrigal Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Madrigal Pharmaceuticals 並不在名單上。</p>
<p>雖然 Madrigal Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Madrigal制藥

VOYA

<p>Voya Investment Management LLC 在第四季度將其在 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 的持股減少了 77.2%，出售了 33,672 股。出售後，Voya 持有 9,942 股，價值約 307 萬美元。其他機構投資者也調整了他們的持股，FMR LLC 增加了 10.8% 的持股。分析師對 MDGL 維持 “適度買入” 的評級，平均目標價為 416.33 美元。近期內部交易中，公司高管進行了大量股票出售，導致股價下跌了 3.7%</p>

<p>Voya Investment Management LLC cut its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 77.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,942 shares of the biopharmaceutical company's stock after selling 33,672 shares during the period. Voya Investment Management LLC's holdings in Madrigal Pharmaceuticals were worth $3,068,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Voya Investment Management LLC 在最近向證券交易委員會提交的 13F 表格中表示，在第四季度將其在 Madrigal Pharmaceuticals, Inc.（NASDAQ:MDGL - 免費報告）中的股份削減了 77.2%。該基金在此期間售出了 33,672 股後，持有 9,942 股該生物製藥公司的股票。Voya Investment Management LLC 在 Madrigal Pharmaceuticals 的持股在最近一個季度末價值 306.8 萬美元。</p>
</div><ul>
<li>Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon</li>
</ul>
<div class="lb-trans"><ul>
<li>諾和諾德：GLP-1 銷售的新動力即將到來</li>
</ul>
</div><p>Other institutional investors also recently added to or reduced their stakes in the company. FMR LLC grew its stake in Madrigal Pharmaceuticals by 10.8% in the 4th quarter. FMR LLC now owns 867,850 shares of the biopharmaceutical company's stock worth $267,792,000 after acquiring an additional 84,305 shares in the last quarter. Geode Capital Management LLC grew its stake in Madrigal Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 410,578 shares of the biopharmaceutical company's stock worth $126,719,000 after purchasing an additional 4,923 shares in the last quarter. William Blair Investment Management LLC purchased a new position in Madrigal Pharmaceuticals during the 4th quarter worth $114,717,000. Rock Springs Capital Management LP raised its position in Madrigal Pharmaceuticals by 0.8% during the 4th quarter. Rock Springs Capital Management LP now owns 265,212 shares of the biopharmaceutical company's stock valued at $81,836,000 after purchasing an additional 2,150 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its holdings in shares of Madrigal Pharmaceuticals by 38.4% in the 4th quarter. Pictet Asset Management Holding SA now owns 208,484 shares of the biopharmaceutical company's stock worth $64,332,000 after buying an additional 57,886 shares during the period. Hedge funds and other institutional investors own 98.50% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者最近也增持或減持了該公司的股份。FMR LLC 在第四季度將其在 Madrigal Pharmaceuticals 的股份增加了 10.8%。FMR LLC 目前持有 867,850 股該生物製藥公司的股票，價值 267,792,000 美元，此前在上個季度增持了 84,305 股。Geode Capital Management LLC 在第四季度將其在 Madrigal Pharmaceuticals 的股份增加了 1.2%。Geode Capital Management LLC 目前持有 410,578 股該生物製藥公司的股票，價值 126,719,000 美元，此前增持了 4,923 股。William Blair Investment Management LLC 在第四季度購買了 Madrigal Pharmaceuticals 的新頭寸，價值 114,717,000 美元。Rock Springs Capital Management LP 在第四季度將其在 Madrigal Pharmaceuticals 的持倉提高了 0.8%。Rock Springs Capital Management LP 目前持有 265,212 股該生物製藥公司的股票，價值 81,836,000 美元，此前增持了 2,150 股。最後，Pictet Asset Management Holding SA 在第四季度將其在 Madrigal Pharmaceuticals 的持股提高了 38.4%。Pictet Asset Management Holding SA 目前持有 208,484 股該生物製藥公司的股票，價值 64,332,000 美元，此前增持了 57,886 股。對沖基金和其他機構投資者持有該公司 98.50% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>MDGL has been the subject of a number of research reports. JMP Securities reaffirmed a &#34;market outperform&#34; rating and issued a $443.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Thursday, April 24th. B. Riley reissued a &#34;buy&#34; rating and set a $460.00 price objective (up from $422.00) on shares of Madrigal Pharmaceuticals in a report on Friday. Canaccord Genuity Group upped their target price on Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the stock a &#34;buy&#34; rating in a report on Friday. HC Wainwright boosted their price target on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, February 27th. Finally, Citigroup upped their price objective on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Madrigal Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $416.33.</p>
<div class="lb-trans"><p>MDGL 已經成為多份研究報告的主題。JMP Securities 在 4 月 24 日的研究報告中重申了對 Madrigal Pharmaceuticals 的 “市場表現優於大盤” 評級，並給出了 443.00 美元的目標價。B. Riley 在週五重新發布了 “買入” 評級，並將 Madrigal Pharmaceuticals 的目標價從 422.00 美元上調至 460.00 美元。Canaccord Genuity Group 在週五將 Madrigal Pharmaceuticals 的目標價從 394.00 美元上調至 420.00 美元，並給予該股票 “買入” 評級。HC Wainwright 在 2 月 27 日的研究報告中將 Madrigal Pharmaceuticals 的目標價從 400.00 美元上調至 405.00 美元，並給予該股票 “買入” 評級。最後，花旗集團在 2 月 27 日的研究報告中將 Madrigal Pharmaceuticals 的目標價從 378.00 美元上調至 469.00 美元，並給予該股票 “買入” 評級。一位分析師對該股票給予了賣出評級，一位給予了持有評級，九位給予了買入評級。根據 MarketBeat 的數據，Madrigal Pharmaceuticals 目前的平均評級為 “適度買入”，平均目標價為 416.33 美元。</p>
</div><ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><ul>
<li>7 只將推動減肥藥市場的股票</li>
</ul>
</div><p><strong>Read Our Latest Stock Report on Madrigal Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Madrigal Pharmaceuticals 的最新股票報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other news, VP Robert E. Waltermire sold 14,113 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $341.32, for a total value of $4,817,049.16. Following the sale, the vice president now directly owns 3,728 shares of the company's stock, valued at $1,272,440.96. This represents a 79.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director James M. Daly sold 15,470 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $347.45, for a total transaction of $5,375,051.50. Following the transaction, the director now directly owns 1,912 shares of the company's stock, valued at approximately $664,324.40. This trade represents a 89.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,810 shares of company stock valued at $10,610,594 over the last quarter. 22.80% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，副總裁 Robert E. Waltermire 在 3 月 5 日的交易中出售了 14,113 股公司的股票。這些股票以平均價格 341.32 美元出售，總價值為 4,817,049.16 美元。出售後，副總裁現在直接持有 3,728 股公司的股票，價值 1,272,440.96 美元。這代表了其持倉的 79.10% 的減少。該交易在向證券交易委員會的法律文件中披露，該文件可通過 SEC 網站訪問。此外，董事 James M. Daly 在 2 月 27 日的交易中出售了 15,470 股公司的股票。這些股票以平均價格 347.45 美元出售，總交易額為 5,375,051.50 美元。交易後，董事現在直接持有 1,912 股公司的股票，價值約 664,324.40 美元。這筆交易代表了其持倉的 89.00% 的減少。該出售的披露信息可以在這裏找到。內部人士在上個季度出售了 30,810 股公司股票，價值 10,610,594 美元。22.80% 的股票目前由公司內部人士持有。</p>
</div><h2>Madrigal Pharmaceuticals Stock Down 3.7 %</h2>
<div class="lb-trans"><h2>Madrigal Pharmaceuticals 股票下跌 3.7%</h2>
</div><ul>
<li>Analysts see over 50% gains in these 2 mid-cap biotech stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師預計這兩隻中型生物科技股票將獲得超過 50% 的收益</li>
</ul>
</div><p>MDGL stock opened at $315.48 on Friday. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals, Inc. has a 52 week low of $200.08 and a 52 week high of $377.46. The stock has a market capitalization of $6.97 billion, a PE ratio of -12.58 and a beta of -0.69. The firm has a 50 day moving average of $325.65 and a 200 day moving average of $313.96.</p>
<div class="lb-trans"><p>MDGL 股票在週五開盤價為 315.48 美元。該公司的速動比率為 5.93，流動比率為 5.98，債務與股本比率為 0.15。Madrigal Pharmaceuticals, Inc.的 52 周低點為 200.08 美元，52 周高點為 377.46 美元。該股票的市值為 69.7 億美元，市盈率為-12.58，貝塔值為-0.69。該公司有 50 日移動平均線為 325.65 美元，200 日移動平均線為 313.96 美元。</p>
</div><p>Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($3.32) earnings per share for the quarter, beating analysts' consensus estimates of ($3.62) by $0.30. The company had revenue of $137.25 million for the quarter, compared to analysts' expectations of $112.79 million. During the same period last year, the firm earned ($7.38) earnings per share. Sell-side analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals（NASDAQ:MDGL - 獲取免費報告）最近在 5 月 1 日公佈了其季度財報。該生物製藥公司報告本季度每股收益為（3.32 美元），超過分析師一致預期的（3.62 美元）0.30 美元。該公司本季度的收入為 1.3725 億美元，而分析師的預期為 1.1279 億美元。在去年同期，該公司每股收益為（7.38 美元）。賣方分析師預測 Madrigal Pharmaceuticals, Inc.在本年度將發佈-23.47 美元的每股收益。</p>
</div><h2>Madrigal Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Madrigal Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於開發用於治療美國非酒精性脂肪肝炎（NASH）的治療藥物。其主要產品候選藥物為 resmetirom，一種針對肝臟的甲狀腺激素受體β激動劑，目前正在進行 NASH 的第三階段臨牀試驗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Madrigal Pharmaceuticals</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Palantir Earnings: 1 Bullish Signal and 1 Area of Concern</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Madrigal Pharmaceuticals</li>
<li>大型股的定義及投資方式</li>
<li>Meta 在第一季度財報中表現出色 - 注意第二季度的關税影響</li>
<li>加拿大便士股票：它們能讓你致富嗎？</li>
<li>亞馬遜財報：兩個值得喜愛的理由，一個需要謹慎的理由</li>
<li>CD 計算器：定期存款計算器</li>
<li>Palantir 財報：一個看漲信號和一個關注領域</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MDGL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Madrigal Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Madrigal Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Madrigal Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Madrigal Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Madrigal Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Madrigal Pharmaceuticals 並不在名單上。</p>
</div><p>While Madrigal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Madrigal Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Voya Investment Management LLC 出售了 33,672 股 Madrigal 製藥公司（納斯達克代碼：MDGL）的股票